NXL
Nexalin Technology, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$5.06
−5.60%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 217.2K | 301.6K | 168.7K | 110.7K | 1.3M |
| Cost of Revenue | 539.5K | 61.4K | 36.6K | 25.7K | 363.2K |
| Gross Profit | (322.3K) | 240.3K | 132.1K | 85.1K | 958.1K |
| Operating Expenses | |||||
| R&D Expense | 1.4M | 1.1M | 1.2M | 1.9M | 511.0K |
| SG&A Expense | 6.5M | 7.5M | 6.7M | 3.9M | 2.8M |
| General & Admin Expense | 2.1M | 1.3M | 966.8K | 574.6K | 2.8M |
| Selling & Marketing Expense | 4.4M | 6.3M | 5.7M | 3.3M | — |
| Other Expenses | 909.2K | — | (116.00) | (189.00) | (511.0K) |
| Total Operating Expenses | 8.8M | 8.6M | 7.9M | 5.8M | 2.8M |
| Cost and Expenses | 9.3M | 8.7M | 7.9M | 5.8M | 3.2M |
| Operating Income (EBIT) | (9.1M) | (8.4M) | (7.8M) | (5.7M) | (1.8M) |
| Non-Operating | |||||
| Interest Income | 322.00 | 8.2K | 3.2K | — | — |
| Interest Expense | — | — | — | 38.8K | 59.4K |
| Net Interest Income | 322.00 | 8.2K | 3.2K | (38.8K) | (59.4K) |
| Other Non-Op Income/Expense | 137.2K | 168.7K | 147.5K | 1.0M | 135.2K |
| Non-Operating Income (excl Interest) | (137.2K) | (168.7K) | (147.5K) | (1.1M) | (194.6K) |
| EBT (Pre-Tax Income) | (9.0M) | (8.2M) | (7.6M) | (4.6M) | (1.7M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (9.0M) | (8.2M) | (7.6M) | (4.6M) | (1.7M) |
| Earnings from Cont. Ops | (9.0M) | (8.2M) | (7.6M) | (4.6M) | (1.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (9.0M) | (8.2M) | (7.6M) | (4.6M) | (1.7M) |
| Per Share | |||||
| Basic EPS | ($14.40) | ($15.00) | ($24.90) | ($18.90) | ($6.90) |
| Diluted EPS | ($14.40) | ($15.00) | ($24.90) | ($18.90) | ($6.90) |
| Revenue Per Share | $0.31 | $0.55 | $0.55 | $0.45 | $5.44 |
| Shares | |||||
| Basic Shares Outstanding | 704764 | 546415 | 307192 | 245234 | 242885 |
| Diluted Shares Outstanding | 704764 | 546415 | 307192 | 245234 | 242885 |
| Profitability Metrics | |||||
| EBITDA | (9.0M) | (8.2M) | (7.6M) | (4.6M) | (1.6M) |
| D&A | 22.5K | 21.5K | 15.1K | 4.3K | 5.7K |
| EBIT | (9.0M) | (8.2M) | (7.6M) | (4.6M) | (1.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026